{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:13:40Z","timestamp":1789586020722,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.ejpb.2013.09.002","type":"journal-article","created":{"date-parts":[[2013,9,27]],"date-time":"2013-09-27T02:15:56Z","timestamp":1380248156000},"page":"942-951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"PB","title":["Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats"],"prefix":"10.1016","volume":"85","author":[{"given":"Line Hagner","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzu","family":"Selen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Rades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"M\u00fcllertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2013.09.002_b0005","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ejpb.2011.12.011","article-title":"New oral solid dosage form for furosemide oral administration","volume":"80","author":"Perioli","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2013.09.002_b0010","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1002\/jps.21352","article-title":"Characterization of amorphous API:polymer mixtures using X-ray powder diffraction","volume":"97","author":"Newman","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2013.09.002_b0015","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1021\/jm0706416","article-title":"Poorly soluble marketed drugs display solvation limited solubility","volume":"50","author":"Bergstrom","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2013.09.002_b0020","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.addr.2007.05.010","article-title":"Salt formation to improve drug solubility","volume":"59","author":"Serajuddin","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2013.09.002_b0025","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1002\/jps.22154","article-title":"Drug supersaturation in simulated and human intestinal fluids representing different nutritional states","volume":"99","author":"Bevernage","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2013.09.002_b0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2013.09.002_b0035","first-page":"75","article-title":"Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract","volume":"46","author":"Horter","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2013.09.002_b0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0378-5173(90)90185-7","article-title":"Physiochemical characterization of furosemide modifications","volume":"60","author":"Matsuda","year":"1990","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2013.09.002_b0045","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/jps.22805","article-title":"Novel furosemide cocrystals and selection of high solubility drug forms","volume":"101","author":"Goud","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2013.09.002_b0050","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/jps.22030","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: furosemide","volume":"99","author":"Granero","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2013.09.002_b0055","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1007\/s11095-008-9679-z","article-title":"Miniaturized rotating disk intrinsic dissolution rate measurement: effects of buffer capacity in comparisons to traditional wood\u2019s apparatus","volume":"25","author":"Avdeef","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2013.09.002_b0060","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0378-5173(02)00586-0","article-title":"Physicochemical characterization of solid dispersion of furosemide with TPGS","volume":"251","author":"Shin","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2013.09.002_b0065","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1081\/DDC-100101274","article-title":"PVP solid dispersions for the controlled release of furosemide from a floating multiple-unit system","volume":"26","author":"Iannuccelli","year":"2000","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2013.09.002_b0070","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00630286","article-title":"Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis","volume":"26","author":"Hammarlund","year":"1984","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2013.09.002_b0075","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/bod.2510090209","article-title":"Comparative bioavailability of furosemide from solution and 40mg tablets with different dissolution characteristics following oral administration in normal men","volume":"9","author":"Waller","year":"1988","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejpb.2013.09.002_b0080","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/BF00615967","article-title":"Reduced bioavailability and effect of furosemide given with food","volume":"29","author":"Beermann","year":"1986","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2013.09.002_b0085","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1046\/j.1365-2125.1996.00494.x","article-title":"Effect of food on the absorption of frusemide and bumetanide in man","volume":"42","author":"McCrindle","year":"1996","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2013.09.002_b0090","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1023\/A:1016427321532","article-title":"Influence of tablet dissolution on furosemide bioavailability: a bioequivalence study","volume":"4","author":"McNamara","year":"1987","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2013.09.002_b0095","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ejps.2011.08.023","article-title":"Effect of counterions on the properties of amorphous atorvastatin salts","volume":"44","author":"Sonje","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2013.09.002_b0100","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1002\/jps.21650","article-title":"Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?","volume":"98","author":"Brouwers","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2013.09.002_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jps.2600660104","article-title":"Pharmaceutical salts","volume":"66","author":"Berge","year":"1977","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2013.09.002_b0110","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1208\/s12249-010-9499-4","article-title":"Analysis of relationships between solid-state properties, counterion, and developability of pharmaceutical salts","volume":"11","author":"Guerrieri","year":"2010","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2013.09.002_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/js9601896","article-title":"Characteristics and significance of the amorphous state in pharmaceutical systems","volume":"86","author":"Hancock","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2013.09.002_b0120","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1023\/A:1015310213887","article-title":"Influence of alkali metal counterions on the glass transition temperature of amorphous indomethacin salts","volume":"19","author":"Tong","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2013.09.002_b0125","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s11095-009-0021-1","article-title":"Understanding the behavior of amorphous pharmaceutical systems during dissolution","volume":"27","author":"Alonzo","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2013.09.002_b0130","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijpharm.2004.06.009","article-title":"Stability study of amorphous valdecoxib","volume":"282","author":"Ambike","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2013.09.002_b0135","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1007\/s11095-006-9086-2","article-title":"Analysis of amorphous and nanocrystalline solids from their X-ray diffraction patterns","volume":"23","author":"Bates","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2013.09.002_b0140","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/jps.20926","article-title":"Correlations between molecular mobility and chemical stability during storage of amorphous pharmaceuticals","volume":"96","author":"Yoshioka","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2013.09.002_b0145","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1021\/mp2002973","article-title":"Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen","volume":"8","author":"Lobmann","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2013.09.002_b0150","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ijpharm.2010.02.029","article-title":"Influence of polymer content on stabilizing milled amorphous salbutamol sulphate","volume":"391","author":"Balani","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2013.09.002_b0155","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1211\/0022357011775532","article-title":"Characterization of glass solutions of poorly water-soluble drugs produced by melt extrusion with hydrophilic amorphous polymers","volume":"53","author":"Forster","year":"2001","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2013.09.002_b0160","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/03639040701484627","article-title":"Melt extrusion and spray drying of carbamazepine and dipyridamole with polyvinylpyrrolidone\/vinyl acetate copolymers","volume":"34","author":"Patterson","year":"2008","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2013.09.002_b0165","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.2042-7158.1992.tb05483.x","article-title":"Amorphism and physiochemical stability of spray-dried frusemide","volume":"44","author":"Matsuda","year":"1992","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2013.09.002_b0170","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s11095-008-9569-4","article-title":"Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update","volume":"25","author":"Jantratid","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2013.09.002_b0175","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/j.2042-7158.2010.01023.x","article-title":"Characterising the behaviour of poorly water soluble drugs in the intestine: application of biorelevant media for solubility, dissolution and transport studies","volume":"62","author":"Kleberg","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2013.09.002_b0180","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1023\/A:1011910801212","article-title":"Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs","volume":"15","author":"Galia","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2013.09.002_b0185","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1021\/ja02086a003","article-title":"The rate of solution of solid substances in their own solutions","volume":"19","author":"Noyes","year":"1897","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejpb.2013.09.002_b0190","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1002\/jps.1150","article-title":"A study of amorphous molecular dispersions of indomethacin and its sodium salt","volume":"90","author":"Tong","year":"2001","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2013.09.002_b0195","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1023\/A:1018985110956","article-title":"Solid-state characteristics of amorphous sodium indomethacin relative to its free acid","volume":"16","author":"Tong","year":"1999","journal-title":"Pharm. Res."},{"issue":"Suppl. 2","key":"10.1016\/j.ejpb.2013.09.002_b0200","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/S0928-0987(00)00181-0","article-title":"In vitro\u2013in vivo correlations for lipophilic, poorly water-soluble drugs","volume":"11","author":"Dressman","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2013.09.002_b0205","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ejps.2011.04.016","article-title":"Intestinal drug solubility estimation based on simulated intestinal fluids: comparison with solubility in human intestinal fluids","volume":"43","author":"Clarysse","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2013.09.002_b0210","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ijpharm.2003.10.016","article-title":"Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugs","volume":"270","author":"Yu","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2013.09.002_b0215","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/jps.22074","article-title":"Drug\u2013polymer solubility and miscibility: stability consideration and practical challenges in amorphous solid dispersion development","volume":"99","author":"Qian","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2013.09.002_b0220","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1002\/jps.22217","article-title":"The developability classification system: application of biopharmaceutics concepts to formulation development","volume":"99","author":"Butler","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2013.09.002_b0225","first-page":"381","article-title":"Furosemide (frusemide). A pharmacokinetic\/pharmacodynamic review (Part I)","volume":"18","author":"Ponto","year":"1990","journal-title":"Clin. Pharmacokinet."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641113002956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641113002956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T13:24:52Z","timestamp":1539350692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641113002956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0939641113002956"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2013.09.002","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2013.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}